Editorial

Risk factors for hepatocellular carcinoma in HCV-cirrhosis: What we know and what is missing

We examined the effect of the hepatitis C virus (HCV) peptide vaccine IC41 on HCV-specific T-cell responses and virological relapse rates in patients with chronic HCV genotype 1 infection when added to pegylated interferon plus ribavirin standard therapy. 35 patients received 6 vaccinations with IC41 from weeks 28 to 48 of standard antiviral treatment and were followed-up for another 6 months. IC41 vaccination did not prevent HCV-RNA relapse in patients with ongoing interferon standard treatment but HCV-specific T-cell responses were inducible and were associated with lower relapse rates. An increase of HCV-specific T-cell responses occurred in 73% of patients, responses were more frequent and stronger in patients with sustained virologic response than in patients who relapsed. Optimized vaccine responses may enhance sustained virologic response rates obtained with standard treatment of chronic hepatitis C.

copper, zinc, iron, and other nine trace elements (TEs) in 30 patients with hepatocellular carcinoma (HCC) were determined from the HCC itself and the surrounding liver parenchyma (SLP) using particle induced X-ray emission (PIXE). The result showed that the level of Zn, Fe, Co, Ca, Mn, Rb, and Cl in HCC significantly differed from that in the SLP (P<0.01), while no notable change has been observed in content of Cu (P=0.9). However, in relation to tumor size, an imbalance Cu distribution was observed. The content of Cu present in small HCC (<35 mm in average diameter) was greater than that in SLP (P<0.4), and when HCC progressed to large one (>35 mm in average diameter), hepatic Cu was no longer accumulated. Other elements such as Zn and Fe, showed no change in concentration relative to tumor size. The significance of the critical HCC size where a change from accumulation to loss in Cu contents is seen is also discussed.